LSBio

10/05/2022

We’re excited to share LSBio is now part of Absolute Biotech, a new company that unites multiple life science brands into one organization specializing in antibody reagents and services. It is still very much business as usual for our customers and partners, but we’re excited for what the future holds. Learn more at absolutebiotech.com.

01/29/2021

Cervical cancer is the fourth most common cancer among women globally and is diagnosed in over 13,000 women in the United States alone each year. Nearly all cases of cervical cancer can be attributable to long lasting infection with certain types of human papillomavirus (HPV).

Check out the LSBio overview of human papillomavirus and full catalog of HPV specific research reagents.
https://www.lsbio.com/research-areas/infectious-disease/papillomaviridae

01/21/2021

We’re excited to share Absolute Antibody and its sister company Kerafast have been acquired by the reagent company | LifeSpan BioSciences, Inc.! It is still very much business as usual for our customers and partners, and the acquisition will enable us to continue the rapid growth of our recombinant antibody catalog and services.

LSBio (LSBio™), a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Redcar, UK-based Absolu

12/03/2020

Dec 1st is World AIDS Day! The current COVID-19 pandemic has made it more difficult than ever for PLHIV (people living with HIV) to access testing and adequate treatment. The impact of the pandemic is particularly devastating to people living in resource-constrained settings, like sub-Saharan Africa, where its effects are compounded by high poverty rates, inadequately resourced health systems, and co-occurring HIV epidemics. Service disruptions for HIV testing and treatment can result in an increase in HIV-related deaths and onward transmission. The following article explores the impact of the COVID-19 pandemic on HIV testing for sexual partners of persons diagnosed HIV+ and Assisted Partner Notification Services (aSP), and outlines a large-scale aPS implementation project and HIV self-test (HIVST) distribution in Western Kenya: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265868/

12/01/2020

November is Lung Cancer awareness month. Did you know Lung cancer is the second most common cause of cancer deaths in the U.S.? It exists as three subtypes: non-small cell lung cancers (NSCLC), which are comprised of the adenocarcinoma and squamous cell carcinoma subtypes that together account for 75% of cases, and small cell lung cancers (neuroendocrine origin) which account for the remainder. The availability of targeted therapies makes it essential to correctly subtype NSCLCs. IHC markers such as NKX2-1 can be used to identify the subtype in cases where the morphology is unclear, or with biopsies where there is insufficient material to make the diagnosis. NKX2-1 (also known as TTF-1) is a transcription factor with a necessary function in the differentiation of lung, thyroid and forebrain cells, and it regulates the expression of surfactant proteins in the lung that are required for host defense and stability. NKX2-1 is a useful cancer marker for distinguishing a primary adenocarcinoma from other metastases, particularly when combined with Napsin A in a marker panel. It is often expressed in adenocarcinoma, where expression is correlated with EGFR mutation and also higher rates of survival in some patients.

Check out LSBio’s top recommended antibody to NKX2-1 / TTF-1 for use in immunohistochemistry: https://www.lsbio.com/pathplus-antibodies/anti-nkx2-1-antibody-thyroid-specific-tf-antibody-aa1-30-flow-ihc-wb-western-ihc-plus-ls-b10666/295331

11/13/2020

Bromodeoxyuridine (BrdU) is a thymidine analog that is selectively incorporated into the DNA of proliferating cells, providing a marker for DNA replication during the S-phase of the cell cycle. This allows for the easy quantification of actively proliferating cells in cell lysates, cell suspensions, and tissue sections, and provides additional information such as cell number, morphology, and cellular antigen analysis from a single culture. BrdU replaces traditional [3H] thymidine incorporation assays, eliminating the limitations of a slow, labor intensive procedure, expensive equipment, and the handling and disposal of radioisotopes. Our BrdU Immunohistochemistry Kit LS-K1085 can be used for staining in vivo BrdU labeled tissues (formalin-fixed paraffin-embedded (FFPE) or frozen sections), or in vitro labeled cultured cells. BrdU incorporated into newly synthesized DNA strands is detected using a biotinylated antibody, followed by a Streptavidin-HRP conjugate and visualization with DAB (diaminobenzidine) substrate and a Hematoxylin counter-stain.

Check out LSBio’s best-selling BrdU assay kit, offered in collaboration with Exalpha Biologicals:
https://www.lsbio.com/assaykits/brdu-immunohistochemistry-kit-ls-k1085/1085

10/31/2020

Closing out Breast Cancer awareness month with a look at the EGFR (Epidermal Growth Factor Receptor) protein. EGFR (HER1) is a transmembrane glycoprotein that constitutes one of four members of the ErbB family of tyrosine kinase receptors. EGFR protein regulates a number of fundamental cell cycle pathways and is involved in migration and tumor invasion. Gene amplification of EGFR is a frequent occurrence in some types of breast cancer and also in numerous other tissues. Roughly half of triple negative and IBC (inflammatory breast cancer) cases show overexpression of this protein. Expression is generally associated with the basal subtype but is also seen in some luminal B tumors, and is correlated with lower ER / PR expression. Although present in normal cells, overexpression of EGFR is a predictor of advanced stage and metastatic potential in breast cancers, and has been associated with decreased survival. EGFR activation also plays a role in resistance to chemotherapy and radiation treatment in tumor cells. Antibodies to this target have been found to perform well in metastatic breast carcinomas.

Click the link to see LSBio’s top recommended antibody to EGFR for use in immunohistochemistry: https://www.lsbio.com/antibodies/ihc-plus-egfr-antibody-c-terminus-ihc-ls-a9400/4043

10/23/2020

HER2 (ERBB2), or human epidermal growth factor receptor 2, is a tyrosine kinase receptor in the epidermal growth factor receptor family that is overexpressed and mutated in approximately 10-20% of breast cancers. It is associated with a more aggressive disease, higher recurrence rate, and increased mortality. ERBB2 (HER2) exhibits positive membranous staining in malignant cells, where it promotes cancer cell growth. Immunohistochemistry staining of ERBB2 is used alongside the proteins ER (estrogen receptor), PR (progesterone receptor) and Ki-67 to classify different subtypes of breast cancer, and it is a widely used prognostic marker for breast cancer, as levels of ERBB2 expression predict a patient’s response to Herceptin therapy.

Click here to see LSBio’s top recommended antibody to HER2 for use in immunohistochemistry: https://www.lsbio.com/pathplus-antibodies/anti-erbb2-antibody-her2-antibody-aa1243-1255-ihc-ip-wb-western-ihc-plus-ls-b2133/62386

10/13/2020

October is Breast Cancer Awareness month! Breast cancer is the most common malignancy in women worldwide and the second leading cause of cancer deaths in women in the United States. Classification is based upon microscopic diagnosis and staining with immunohistochemistry (IHC) markers such as HER2 (ERBB2), Estrogen Receptor (ESR1), and Progesterone Receptor (PR). Markers are also used to determine if a cancer is invasive, to subtype ductal and lobular carcinomas, to demonstrate mammary origin for a breast cancer, study tumor proliferation or apoptosis, angiogenesis, immune reaction to the tumor, and to study genes upregulated in hereditary breast cancer.

For a list of our antibodies to critical breast cancer markers, visit: https://www.lsbio.com/research-areas/breast-cancer-ihc-markers.

10/02/2020

Looking for personal protective equipment? Keep your workforce safe with LSBio’s catalog of high quality, affordable PPE.

You can minimize exposure to infectious viral particles and risk of hazardous liquid splashes with a variety of protective equipment. We offer KN95 masks, surgical masks, face shields, nitrile gloves, latex gloves, gowns, and more. Our masks have been independently tested and confirmed to meet the KN95 standard, effectively filtering 95% of airborne particles. Discounts are available for healthcare professionals and first responders.

Click here to explore our catalog of Researcher PPE https://www.lsbio.com/ppe

Need a different kind of PPE?
Email us customer.support@LSBio.com
Or call (206) 374-1102

09/25/2020

A multi-site, Phase 3 clinical trial evaluating an investigational COVID-19 vaccine, AZD1222, has begun. The vaccine was developed by Oxford University’s Jenner Institute and Oxford Vaccine Group and has been licensed to AstraZeneca, a United Kingdom-based global biopharmaceutical company, for further development. The vaccine uses a non-replicating chimpanzee adenovirus to deliver a SARS-CoV-2 spike protein to induce an immune response. The trial will enroll approximately 30,000 adult volunteers at 80 sites in the United States to evaluate if the candidate vaccine can prevent symptomatic COVID-19. The vaccine candidate will also be evaluated for its ability to prevent SARS-CoV-2 infection regardless of symptoms as well as preventing severe COVID-19 disease.

Click to read more on the Phase 3 clinical testing in the US of AstraZeneca COVID-19 Vaccine Candidate: https://www.nih.gov/news-events/news-releases/phase-3-clinical-testing-us-astrazeneca-covid-19-vaccine-candidate-begins

09/03/2020

What do we know about the peripheral immune response to severe COVID-19 cases? Approximately 20% of COVID -19 patients develop severe disease, and 5% require intensive care. Severe cases are associated with numerous changes in peripheral immune activity, including increased levels of pro-inflammatory monocytes, lymphopenia and T-cell exhaustion. In an effort to understand the role of peripheral monocytes and lymphocytes in the expression pattern of pro-inflammatory cytokines, researchers have applied single cell RNA sequencing to profile peripheral blood mononuclear cells from COVID-19 patients. They found that peripheral monocytes and lymphocytes do not express substantial amounts of pro-inflammatory cytokines.

Click to review their cell atlas of the peripheral immune response to severe COVID-19
https://www.nature.com/articles/s41591-020-0944-y

Click to explore coronavirus research products from LSBio
https://www.lsbio.com/research-areas/infectious-disease/coronavirus

Don’t forget to Like our page for more coronavirus research updates.

Single-cell transcriptomic analysis identifies changes in peripheral immune cells in seven hospitalized patients with COVID-19, including HLA class II downregulation, a heterogeneous interferon-stimulated gene signature and low pro-inflammatory cytokine gene expression in monocytes and lymphocytes.

08/07/2020

Lipopolysaccharide / LPS (Sandwich ELISA) ELISA Kit - LS-F17912
https://www.lsbio.com/elisakits/lipopolysaccharide-lps-sandwich-elisa-elisa-kit-ls-f17912/17912

Lipopolysaccharide (LPS), also known as endotoxin, is the major component of Gram-negative bacteria that activates mammalian immune systems. It is a strong mediator of systemic inflammation and contributes to septic shock. Shock is induced by circulating pro-inflammatory and pro-apoptotic mediators released by immune cells after coming into contact with LPS. Toll-like receptors on the immune cells contribute to the severe inflammatory response observed in these patients.

During sepsis, endotoxin can lead to a dysregulated host response to the infection, which then leads to an imbalance between pro- and anti-inflammatory mechanisms, resulting in multi-organ dysfunction.

“Lipopolysaccharide (LPS) induced inflammatory response and progression towards multi-organ dysfunction.” https://www.karger.com/Article/FullText/480424

07/31/2020

How are nucleoside analogue inhibitors like Remdesivir being utilized in the battle against COVID-19?

RNA viruses require their own RNA-dependent RNA polymerase (RdRp) to replicate. Humans do not have RdRp, making this an ideal target for antiviral drugs like Remdesivir. Remdesivir is a nucleoside analog which inhibits viral replication by causing termination of viral genome replication after it is incorporated by RdRP (McKee, 2020; Shannon, 2020; Warren, 2016).

Find Remdesivir and other Nucleoside analogue inhibitors at lsbio.com

Remdesivir: https://www.lsbio.com/biochemicals/gs-5734-remdesivir-cas-1809249-37-3-ls-h17669/17669
Sars-CoV-2 Inhibitors: https://www.lsbio.com/research-areas/infectious-disease/coronavirus/disease-inhibitors
SARS-CoV-2 and COVID-19 Pathogenesis: A Review
https://www.lsbio.com/Content/Documents/Media/WhitePapers/SARS-CoV-2-And-COVID-19-Pathogenesis-A-Review.pdf

07/23/2020

Researchers worldwide are investigating SARS-CoV-2 virus, its mechanism of action, and how it causes COVID-19 disease. LSBio’s chief pathologist Dr. Glenna Burmer and bioinformaticians Mark Burmer and Vagmita Pabuwal have written a comprehensive review of SARS-CoV-2 and its involvement in the pathogenesis of COVID-19 disease. Topics include the viral life cycle, the phylogeny of coronaviruses, clinical features, pathogenesis and progression, inhibitors for treatment, and the efficacy of personal protective equipment. Read about SARS-CoV-2 and how it causes COVID-19 in the link below.

SARS-CoV-2 and COVID-19 Pathogenesis: A Review
https://www.lsbio.com/Content/Documents/Media/WhitePapers/SARS-CoV-2-And-COVID-19-Pathogenesis-A-Review.pdf